Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Martin Reck, Sanjay Popat, Niels Reinmuth et al. · Annals of Oncology · 2014
Cited by 679 works. doi:10.1093/annonc/mdu199
Authors
References
- Global cancer statistics
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial